For laboratory research use only. Not for human or animal consumption.
BioIntegrityResearch
Current lot>99.0% purity

CJC-1295 / Ipamorelin

Analytical results for lot CI1010N1125 (15 mL nasal spray), third-party tested by AxisPharm, LLC and reported 2025-11-13.

Analytical results for lot CI1010N1125
AssayMethodResult
PurityHPLC-UV (208 nm)>99.0%
Identity — CJC-1295LC-MS (ESI+)1124.4 [M+3H], 844.0 [M+4H]
Identity — IpamorelinLC-MS (ESI+)714.3 [M+H]

Lot record

Lot numberCI1010N1125
CompoundCJC-1295 / Ipamorelin
Format15 mL nasal spray
Label claim10 mg / 10 mg
Measured content9.2 / 9.3 mg
Expected mass3367.9 / 711.8 g/mol
Report date2025-11-13
Sample received2025-11-13
Manufactured2025-11
Best before2026-11
ManufactureGMP-compliant peptide manufacturing facility, United States
Third-party analysisAxisPharm, LLC
StatusCurrent — in stock

Note. CJC-1295 without DAC (Modified GRF 1-29). Expected mass 3367.9 g/mol.

Compound

A prepared blend pairing a GHRH analogue with a selective ghrelin receptor secretagogue.

CJC-1295 / Ipamorelin specification →

Other lots of CJC-1295 / Ipamorelin

Lot-to-lot comparison across releases.

CI710V1125
10 mL vial · reported 2025-11-03 · Current
>99.0%

The certificate for this lot

The results above are published in full. The certificate itself is the testing laboratory’s document, and we supply it per batch rather than as a public download — so a certificate can only ever travel with the material it describes. If you hold or are purchasing lot CI1010N1125, request it and we will send it.

Request the certificate for CI1010N1125

All compounds supplied by BioIntegrity Research are intended strictly for laboratory research and educational use. Not for human or animal consumption. Not for diagnostic, therapeutic, or clinical use. No statement on this website has been evaluated by the Food and Drug Administration. Purchaser affirms that products are acquired solely for legitimate laboratory research and assumes full responsibility for lawful handling, storage, and disposal.